Substance / Medication

Sulfacetamide

Overview

Active Ingredient
sulfacetamide
RxNorm CUI
10169

Indications

INDICATIONS: Sodium Sulfacetamide 9% - Sulfur 4% Wash is indicated in the topical control of acne vulgaris, acne rosacea and seborrheic dermatitis.

Labeler: ACELLA PHARMACEUTICALSUpdated: 2024-01-10T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

CONTRAINDICATIONS: Sodium Sulfacetamide 9% - Sulfur 4% Wash is contraindicated for use by patients having known hypersensitivity to sulfonamides, sulfur or ony other component of this preparation. Sodium Sulfacetamide 9% - Sulfur 4% Wash is not to be used by patients with kidney disease.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

1 trials linked to this intervention

1
Total Trials
0
Recruiting
1
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Interaction of topical sulfacetamide and topical dapsone with benzoyl peroxide.
Dubina Meghan I, Fleischer Alan B · Arch Dermatol · 2009
PMID: 19770443Observational
Optimal conditions for determination of zinc bacitracin, polymyxin B, oxytetracycline and sulfacetamide in animal feed by micellar electrokinetic capillary chromatography.
Injac Rade, Mlinaric Ales, Djorjevic-Milic Vukosava et al. · Food Addit Contam Part A Chem Anal Control Expo Risk Assess · 2008
PMID: 18348041Observational
The use of sodium sulfacetamide 10%-sulfur 5% emollient foam in the treatment of acne vulgaris.
Del Rosso James Q · J Clin Aesthet Dermatol · 2009
PMID: 20729951Case ReportFull text (PMC)
Synthesis of a new magnetic Sulfacetamide-Ethylacetoacetate hydrazone-chitosan Schiff-base for Cr(VI) removal.
Eltaweil Abdelazeem S, Hashem Omar A, Abdel-Hamid Hamida et al. · Int J Biol Macromol · 2022
PMID: 36113599Other

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Sulfacetamide (substance)
SNOMED CT
372676007
UMLS CUI
C0038670
RxNorm CUI
10169
Labeler
ACELLA PHARMACEUTICALS

Clinical Data

This intervention maps to 5 entities in the Healos knowledge graph.

5
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
1
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.

Sulfacetamide — Conditions, Biomarkers & Specialists | Healos | Healos